Eli Lilly announced that its investigational oral GLP-1 receptor agonist, orforglipron, met primary and key secondary endpoints in two Phase 3 clinical trials evaluating its efficacy and safety in adults with type 2 diabetes. The data showed that orforglipron provided superior glycemic control and significant reductions in body weight compared with placebo and active comparators, underscoring its potential as a foundational therapy for diabetes management.
The first trial assessed orforglipron in adults inadequately controlled on metformin, while the second evaluated patients receiving additional background therapies. Both studies demonstrated statistically significant improvements in HbA1c levels, with many participants achieving glycemic targets below 7%. Weight reductions were consistent with those seen in injectable GLP‑1 therapies, reinforcing the candidate’s comprehensive metabolic benefits.
Lilly highlighted that orforglipron’s once-daily oral formulation could address a key unmet need by offering GLP‑1 efficacy without the need for injection. The company plans to submit regulatory applications in major markets beginning in 2026.
“The consistency of these findings across multiple Phase 3 studies reinforces our confidence in orforglipron’s role as a next-generation treatment for people with type 2 diabetes,” the company stated.
If approved, orforglipron would mark the first non-peptide, orally administered GLP‑1 receptor agonist to reach the market, expanding access to the proven benefits of this drug class and potentially reshaping early treatment strategies in type 2 diabetes care.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!